276 related articles for article (PubMed ID: 15838626)
1. The role of fibroblast growth factor 23 for hypophosphatemia and abnormal regulation of vitamin D metabolism in patients with McCune-Albright syndrome.
Yamamoto T; Imanishi Y; Kinoshita E; Nakagomi Y; Shimizu N; Miyauchi A; Satomura K; Koshiyama H; Inaba M; Nishizawa Y; Jüppner H; Ozono K
J Bone Miner Metab; 2005; 23(3):231-7. PubMed ID: 15838626
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.
Jonsson KB; Zahradnik R; Larsson T; White KE; Sugimoto T; Imanishi Y; Yamamoto T; Hampson G; Koshiyama H; Ljunggren O; Oba K; Yang IM; Miyauchi A; Econs MJ; Lavigne J; Jüppner H
N Engl J Med; 2003 Apr; 348(17):1656-63. PubMed ID: 12711740
[TBL] [Abstract][Full Text] [Related]
3. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis.
Shimada T; Hasegawa H; Yamazaki Y; Muto T; Hino R; Takeuchi Y; Fujita T; Nakahara K; Fukumoto S; Yamashita T
J Bone Miner Res; 2004 Mar; 19(3):429-35. PubMed ID: 15040831
[TBL] [Abstract][Full Text] [Related]
4. Fibrous dysplasia, phosphate wasting and fibroblast growth factor 23.
Imel EA; Econs MJ
Pediatr Endocrinol Rev; 2007 Aug; 4 Suppl 4():434-9. PubMed ID: 17982392
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast growth factor-23 is regulated by 1alpha,25-dihydroxyvitamin D.
Collins MT; Lindsay JR; Jain A; Kelly MH; Cutler CM; Weinstein LS; Liu J; Fedarko NS; Winer KK
J Bone Miner Res; 2005 Nov; 20(11):1944-50. PubMed ID: 16234967
[TBL] [Abstract][Full Text] [Related]
6. Levels and dynamic changes of serum fibroblast growth factor 23 in hypophosphatemic rickets/osteomalacia.
Xia WB; Jiang Y; Li M; Xing XP; Wang O; Hu YY; Zhang HB; Liu HC; Meng XW; Zhou XY
Chin Med J (Engl); 2010 May; 123(9):1158-62. PubMed ID: 20529556
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor 23 and its receptors.
Yu X; White KE
Ther Apher Dial; 2005 Aug; 9(4):308-12. PubMed ID: 16076372
[TBL] [Abstract][Full Text] [Related]
8. Resolution of severe, adolescent-onset hypophosphatemic rickets following resection of an FGF-23-producing tumour of the distal ulna.
Ward LM; Rauch F; White KE; Filler G; Matzinger MA; Letts M; Travers R; Econs MJ; Glorieux FH
Bone; 2004 May; 34(5):905-11. PubMed ID: 15121023
[TBL] [Abstract][Full Text] [Related]
9. Expression of FGF23 is correlated with serum phosphate level in isolated fibrous dysplasia.
Kobayashi K; Imanishi Y; Koshiyama H; Miyauchi A; Wakasa K; Kawata T; Goto H; Ohashi H; Koyano HM; Mochizuki R; Miki T; Inaba M; Nishizawa Y
Life Sci; 2006 Apr; 78(20):2295-301. PubMed ID: 16337659
[TBL] [Abstract][Full Text] [Related]
10. Novel regulators of phosphate homeostasis and bone metabolism.
Jüppner H
Ther Apher Dial; 2007 Oct; 11 Suppl 1():S3-22. PubMed ID: 17976082
[TBL] [Abstract][Full Text] [Related]
11. The journey from vitamin D-resistant rickets to the regulation of renal phosphate transport.
Levine BS; Kleeman CR; Felsenfeld AJ
Clin J Am Soc Nephrol; 2009 Nov; 4(11):1866-77. PubMed ID: 19808223
[TBL] [Abstract][Full Text] [Related]
12. Regulatory mechanisms of circulating fibroblast growth factor 23 in parathyroid diseases.
Imanishi Y; Kobayashi K; Kawata T; Inaba M; Nishizawa Y
Ther Apher Dial; 2007 Oct; 11 Suppl 1():S32-7. PubMed ID: 17976083
[TBL] [Abstract][Full Text] [Related]
13. Oral phosphate supplementation corrects hypophosphatemia and normalizes plasma FGF23 and 25-hydroxyvitamin D3 levels in women with chronic metabolic acidosis.
Domrongkitchaiporn S; Disthabanchong S; Cheawchanthanakij R; Niticharoenpong K; Stitchantrakul W; Charoenphandhu N; Krishnamra N
Exp Clin Endocrinol Diabetes; 2010 Feb; 118(2):105-12. PubMed ID: 19449283
[TBL] [Abstract][Full Text] [Related]
14. Clinical approach to clarifying the mechanism of abnormal bone metabolism in McCune-Albright syndrome.
Yamamoto T
J Bone Miner Metab; 2006; 24(1):7-10. PubMed ID: 16369891
[TBL] [Abstract][Full Text] [Related]
15. Hypophosphatemic rickets accompanying McCune-Albright syndrome: evidence that a humoral factor causes hypophosphatemia.
Yamamoto T; Miyamoto KI; Ozono K; Taketani Y; Katai K; Miyauchi A; Shima M; Yoshikawa H; Yoh K; Takeda E; Okada S
J Bone Miner Metab; 2001; 19(5):287-95. PubMed ID: 11498730
[TBL] [Abstract][Full Text] [Related]
16. Serum FGF23 levels in normal and disordered phosphorus homeostasis.
Weber TJ; Liu S; Indridason OS; Quarles LD
J Bone Miner Res; 2003 Jul; 18(7):1227-34. PubMed ID: 12854832
[TBL] [Abstract][Full Text] [Related]
17. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D metabolism in the kidney: regulation by phosphorus and fibroblast growth factor 23.
Perwad F; Portale AA
Mol Cell Endocrinol; 2011 Dec; 347(1-2):17-24. PubMed ID: 21914460
[TBL] [Abstract][Full Text] [Related]
19. The phosphatonins and the regulation of phosphate transport and vitamin D metabolism.
Sommer S; Berndt T; Craig T; Kumar R
J Steroid Biochem Mol Biol; 2007 Mar; 103(3-5):497-503. PubMed ID: 17224271
[TBL] [Abstract][Full Text] [Related]
20. Correlation among hyperphosphatemia, type II sodium phosphate transporter activity, and vitamin D metabolism in Fgf-23 null mice.
Sitara D
Ann N Y Acad Sci; 2007 Nov; 1116():485-93. PubMed ID: 17646263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
